Status:
COMPLETED
Glycosphingolipid Inhibition and Spermatogenesis in Man: A Pilot Study (MIG 2)
Lead Sponsor:
University of Washington
Collaborating Sponsors:
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Conditions:
Contraception
Eligibility:
MALE
18-50 years
Phase:
PHASE4
Brief Summary
The purpose of this research study is to help in the development of safe, effective and reversible male contraception. We are examining the impact of the drug Miglustat on sperm production in normal m...
Detailed Description
Glycosphingolipids (GSL) are a main constituent of the sperm cell membrane in mammals. Male mice deficient in enzymes involved in GSL synthesis have severely impaired fertility and knockout mice are i...
Eligibility Criteria
Inclusion
- Healthy male, normal lab test
Exclusion
- Abnormal lab test, history or evidence of significant chronic or acute medical illness, previous or current ethanol or anabolic steroid abuse.
Key Trial Info
Start Date :
June 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2006
Estimated Enrollment :
8 Patients enrolled
Trial Details
Trial ID
NCT00194649
Start Date
June 1 2005
End Date
January 1 2006
Last Update
September 19 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Washington
Seattle, Washington, United States, 98195